Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance ...
MediWound’s first drug, NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can ...
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong ...
R. conorii conorrii Rh. sanguineus (I. ricinus) Mediterranean spotted fever Rash (97%); single eschar; case–fatality rate without treatment (0–18%) R. conorii israelensis Rh. sanguineus ...
1 Creighton University School of Medicine Phoenix, Phoenix, AZ, United States 2 Department of Surgery, Valleywise Health Medical Center, Phoenix, AZ, United States Breast-conserving surgery (BCS) is a ...
On the posterior lower leg there was a 8 x 4 cm tender, irregular bordered, jagged red “punched out” plaque with central ulceration and eschar present (see Figure 1). There were a few pinpoint ...
1 Creighton University School of Medicine Phoenix, Phoenix, AZ, United States 2 Department of Surgery, Valleywise Health Medical Center, Phoenix, AZ, United States Breast-conserving surgery (BCS) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback